A record number of people are quitting their jobs across all employment sectors. Alex Brill joins i24News to discuss what the skyrocketing quit rates means for the US economy, and when we can expect the job market to return to normal.
Biosimilars represent a significant cost-savings opportunity in the United States because they can introduce competition for some of the most expensive and widely used prescription drugs on the market: originator biologics. Several market and regulatory barriers have slowed biosimilar market entry and uptake in the United States.
On October 15th, Alex Brill made a special appearance on CNBC’s “Squawk Box” to discuss President Biden’s corporate tax increase and the effects of rising inflation on the U.S. economy.
In his article for Intellectual Asset Management (IAM), Life Sciences Reporter Adam Houldsworth discusses the weaknesses in the US patent system that enable the “thorny” problem of patent thickets. MGA’s report, “How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing,” was featured heavily in the article to provide evidence of the growing problem.
Three policy experts join Richard Rubin of The Wall Street Journal to examine the current iteration of the Build Back Better Act.
The bipartisan infrastructure bill approved by the Senate on August 10 includes a number of budget gimmicks that help make it look fully “paid for.” One of the gimmicks is pension smoothing, which allows private companies to make smaller contributions to their defined-benefit pension plans, thereby endangering the plans’ financial viability over time.
In a new BioWorld article, Mari Serebrov discusses efforts by Congress to control US prescription drug prices. Interviewed for the article was MGA’s Alex Brill, who talks about the potential side effects of such efforts.
Democrats want to increase the corporate tax rate, but is that the best way to generate revenue for the government? AEI’s Alex Brill discusses an alternative tax that could benefit the planet as well.
In Intellectual Asset Management (IAM), Fresenius Kabi Intellectual Property Chief Rachel Moodie discusses the worsening problem of patent thickets in the U.S. biosimilars market. Featured in the article is MGA’s report on patent thickets, as well as a quote from MGA’s Christy Robinson, who voiced her concern regarding the future of the biosimilars market.
This report, from Matrix Global Advisors (MGA), highlights Teva’s impact on economies in 15 of the 60 countries in which Teva operates. These 15 countries comprise 60 percent of Teva’s total global workforce and 75 percent of revenues in 2020. MGA’s detailed impact analysis estimates that, in 2020, Teva’s local purchases and payroll supported more than 249,000 jobs across these 15 countries, contributed $52 billion to economic output, and generated $11.7 billion in labor income.
The new administration is making a big push to support green energy and lower carbon emissions. But are they doing it the right way?
Debating the issue are Christy Goldfuss, senior vice president for energy and environment at the Center for American Progress, and Alex Brill, senior fellow at the American Enterprise Institute.
President Biden’s tax-and-spend infrastructure plan will reduce the competitiveness of U.S. corporations, burden working-class Americans, and discourage the type of private investment in America that fuels economic growth.
The Center for Biosimilars has announced that MGA’s recent report, “How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing,” was the top-read article on its website for the week of June 14, 2021.
On Thursday, The Center for Biosimilars, a sister site of The American Journal of Managed Care, published an article discussing the differences between the patent systems in the United States and Europe when it comes to biosimilars. The article featured the latest report released by MGA, and authored by Alex Brill and Christy Robinson, titled “How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing”:
New White Paper Identifies Patent Thickets as Barrier to US Biosimilars Market and Domestic Manufacturing
“How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing,” authored by Alex Brill and Christy Robinson, explains how reference biologic manufacturers create thickets of overlapping, weaker follow-on patents to keep competitors from entering the market. The paper highlights how originators have strong incentives to protect their profit streams and have found patent thickets to be an easy way to significantly extend the duration of monopolies in the US, preventing access to more affordable medicines for patients.
Have a Question?
Get In Touch
Get Our latest news
1350 Connecticut Avenue NW
Washington, DC 20036